Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics

The second round of generic approvals for Bristol's anti-anxiety drug BuSpar (buspirone) appears to be held up by Bristol's attempts to enforce exclusivity based on a change in labeling related to pediatric studies.